Gastroenterology

Back to articles

New studies assess safety of PPIs, with conflicting results

KEY POINT

Use of proton pump inhibitors (PPIs) was associated with an excess of mortality from cardiovascular (CV) disease, chronic kidney disease (CKD), and upper GI cancer, according to an observational study published in BMJ. However, an experimental trial published in Gastroenterology concluded there were no significant differences in safety between a PPI and placebo except for an increased risk of enteric infections.